Androgenetic alopecia affects both men and women. About 50% of men under the age of 50 and 40% of women over 50 suffer from this problem. Androgenetic alopecia is due to hair follicle miniaturisation under the influence of dihydrotestosterone. The etiology is multifactorial. It is connected, among others, with increased activity of alpha-5-reductase type II and increased DIH in the frontal region, as well as with increased activity of aromatase in the occipital region. In men, a characteristic backward shift of the frontal line or thinning of hair in the apical region is noted. In the case of androgenetic alopecia in women, the clinical picture is different. Here, diffuse alopecia or thinning of hair in the central part of the frontal region, the so-called wide parting syndrome, is most often distinguished.
Treatment of androgenic alopecia is based on pharmacological products that lower the level of DIH and alpha-5-reductase type II, or even type I, administered orally, as well as locally applied preparations improving blood supply to the scalp and extending the anagen phase of the hair growth cycle. Mesotherapy treatments using vitamin cocktails and platelet rich plasma are an ideal supplement to the therapy. These procedures are designed to prolong the growth phase of the hair and also to regenerate damaged and miniaturised hair follicles. When pharmacological treatment, supplemented with mesotherapy treatments, does not bring the desired aesthetic results, it is possible to perform such procedure as hair transplantation using the FUE or S.A.F.E.R. method. During the procedure, follicular units or single follicles are taken from the occipital region and implanted in the areas of thinned hair or hair loss. The procedures are non-invasive, performed under local anaesthesia and require a recovery period of approximately one week. The final effect of androgenic alopecia treatment is visible 9-12 months after the procedure.
What do you need to know?